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MS AHI1 genetic risk promotes IFNg1
CD41 T cells
ABSTRACT
Objective: To study the influence of the Abelson helper integration site 1 (AHI1) locus associated
with MS susceptibility on CD41 T cell function.
Methods: We characterized the chromatin state of T cells in the MS-associated AHI1 linkage
disequilibrium (LD) block. The expression and the role of the AHI1 variant were examined in
T cells from genotyped healthy subjects who were recruited from the PhenoGenetic Project,
and the function of AHI1 was explored using T cells from Ahi1 knockout mice.
Results: Chromatin state analysis reveals that the LD block containing rs4896153, which is
robustly associated with MS susceptibility (odds ratio 1.15, p 5 1.65 3 10213), overlaps with
strong enhancer regions that are present in human naive and memory CD41 T cells. Relative to
the rs4896153A protective allele, the rs4896153T susceptibility allele is associated with
decreased AHI1 mRNA expression, specifically in naive CD41 T cells (p 5 1.73 3 10274, n 5
213), and we replicate this effect in an independent set of subjects (p 5 2.5 3 1029, n 5 32).
Functional studies then showed that the rs4896153T risk variant and the subsequent decreased
AHI1 expression were associated with reduced CD41 T cell proliferation and a specific differen-
tiation into interferon gamma (IFNg)–positive T cells when compared with the protective
rs4896153A allele. This T cell phenotype was also observed in murine CD41 T cells with genetic
deletion of Ahi1.
Conclusions: Our findings suggest that the effect of the AHI1 genetic risk for MS is mediated, in
part, by enhancing the development of proinflammatory IFNg1 T cells that have previously been
implicated in MS and its mouse models. Neurol Neuroimmunol Neuroinflamm 2018;5:e414; doi:
10.1212/NXI.0000000000000414
GLOSSARY
AHI1 5 Abelson helper integration site 1; EAE 5 experimental autoimmune encephalomyelitis; eQTL 5 expression quanti-
tative trait locus; GWAS 5 genome-wide association study; IFNg 5 interferon gamma; IL 5 interleukin; LD 5 linkage
disequilibrium; MFI 5 mean fluorescence intensity; OR 5 odds ratio; PBMC 5 peripheral blood mononuclear cell; PGP 5
PhenoGenetic Project; SNP 5 single nucleotide polymorphism; TCR 5 T cell receptor; TF 5 transcription factor; Th 5
T helper; TSS 5 transcription start site; WT 5 wild type.
MS is a chronic inflammatory disease of the CNS characterized by episodes of neuronal demy-
elination in genetically susceptible individuals on exposure to environmental triggers. Genome-
wide association studies (GWASs) have identified and validated over 110 non–major histo-
compatibility complex genetic variants associated with MS, and many of these are implicated in
the function of CD41 and CD81 T cells that are present in MS lesions.1,2 Considerable work
over the years in studies of patients with MS and in animal models of MS has implicated
proinflammatory CD41 T helper (Th)1 cells (which produce interferon gamma [IFNg]) and
Th17 cells (interleukin [IL]-17-producers) as important mediators of new relapsing disease
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activity.3,4 These 2 types of pathogenic cells are
implicated in MS and could account for some
of the immunologic and clinical heterogeneity
of the disease.5
Recent analysis of Th17 cell development
and pathogenicity revealed a critical role of
IFNg for the severity of the disease in mouse
models of MS. Indeed, in a reporter mouse
model, it has been found that Th17 cells could
play a pathogenic role in MS by converting
their phenotype into a proinflammatory Th1
profile in which committed Th17 cells give
rise to a progeny that shifts toward enhanced
IFNg expression.6 Similarly, in humans, there
is evidence indicating that, in the presence of
IL-12, Th17 cells also produce IFNg. These
cells, which produce both IL-17 and IFNg,
are called Th1/17 cells,7 and, together with
“non-classical Th1 cells,” they might contrib-
ute to disease pathogenesis through properties
shared by both the Th1 and Th17 subsets.8
Moreover, Th17 cells producing IFN-g are
enriched in myelin oligodendrocyte
glycoprotein-specific T cells.9 IFNg produced
by these cells could strongly activate macro-
phages whose infiltration in the CNS corre-
lates with experimental autoimmune
encephalomyelitis (EAE) severity.10
It is necessary to understand the functional
consequences of disease-associated genetic varia-
tions as we strive to unravel the causal chain of
events linking genetic risk factors to clinical syn-
dromes. Separate from GWASs, expression
quantitative trait locus (eQTL) studies have
been used to map a genetic variants contribution
to variation in gene expression.11 However,
moving from a list of eQTL effects to pheno-
typic changes, regulation of disease activity re-
mains challenging and is often unfruitful.
In this study, we integrated results from
large-scale, genome-wide disease gene discov-
ery studies with eQTL studies to identify the
MS susceptibility variant with a transcriptional
effect that influences T cell phenotypes. We
examined such a variant in the MS susceptibil-
ity gene Abelson helper integration site 1
(AHI1) by first characterizing and validating
its cis-eQTL effect, and we go on to demon-
strate that the AHI1 genetic variant is involved
in the regulation of human CD41 T cell pro-
liferation and IFNg production. Furthermore,
we leveraged a mouse model with genetic dele-
tion of Ahi1 to analyze the effects of Ahi1
deficiency on murine CD41 T cell function.
Consistent with the human results, the mouse
results suggest that the mechanism of the
AHI1 genetic risk involves the differentiation
of naive CD41 T cells into proinflammatory
IFNg1 T cells, which could contribute to MS
onset.
METHODS PhenoGenetic Project. The PhenoGenetic Pro-
ject (PGP) is a biobank of healthy individuals, older than 18
years, who are free from chronic inflammatory infections and
metabolic diseases.11 Genotyped individuals (n 5 32) of Euro-
pean descent bearing risk (TT), protective (AA), or heterozygous
(AT) genotypes for rs4896153 were selected from this cohort and
used for this study.
PBMC isolation and CD41 T cell culture. Peripheral
venous blood was obtained from healthy control volunteers in
compliance with protocols approved by the Institutional Review
Board of Partners Healthcare as part of the PGP. Peripheral blood
mononuclear cells (PBMCs) were separated by Ficoll-Paque
PLUS (GE Healthcare, Piscataway, NJ) gradient centrifugation.
PBMCs were frozen at a concentration of 1–3 3 107 cells/mL in
10% DMSO and stored at280°C. CD41CD45RO2CD45RA1
naive T cells were isolated from cryopreserved PBMCs by nega-
tive selection (Miltenyi Biotec, Auburn, CA). Naive CD41
T cells were cultured in 96-well round bottom plates (Costar,
Cambridge, MA) at 2 3 104 cells/well in serum-free X-Vivo 15
medium (BioWhittaker, Walkersville, MD) and stimulated with
plate-bound anti-CD3 OKT3 (BioXCell, 10 mg/mL) and anti-
CD28 (BioXCell, 1 mg/mL) antibodies for 6–8 days.
Mouse CD41 T cell isolation and activation. Ahi12/2 mice
were generated as described previously12 and backcrossed .10
generations onto a Friend Virus B NIH Jackson background.
CD41 T cells were isolated from the spleens of Ahi12/2 and
littermate control mice by negative selection (Miltenyi Biotec,
Auburn, CA) and cultured in 96-well round bottom plates
(Costar, Cambridge, MA) at 1 3 105 cells/well in serum-free
X-Vivo 15 medium (BioWhittaker, Walkersville, MD) supple-
mented with 1:1000 BME and stimulated with plate-bound anti-
CD3 (BioXCell, 0.25–2 mg/mL) and anti-CD28 (BioXCell,
0.25–2 mg/mL) antibodies for 4 days. For Th1 cell polarization,
recombinant IL-12 was used at 10 ng/mL. For Th17 cell polar-
ization, recombinant IL-6 (10 ng/mL) and transforming growth
factor–b1 (3 ng/mL) were used. All recombinant proteins were
from R&D Systems (Minneapolis, MN).
Cytokine measurement by flow cytometry. CD41 T cells
were stimulated for 4 hours with PMA (50 ng/mL) and Ionomy-
cin (250 ng/mL, both from Sigma-Aldrich, St. Louis, MO) in the
presence of GolgiStop (BD Biosciences), then washed and fixed/
permeabilized with Cytofix/Cytoperm (BD Biosciences, San Jose,
CA) according to manufacturer’s instructions. Cells were stained
with 7-AAD (BD Biosciences), or Aqua LIVE/DEAD Fixable
stain (Life Technologies, Carlsbad, CA) and FITC-IFNg (clone
25723; R&D Systems). Data were acquired on a FACSCalibur or
LSRII (BD Biosciences) and analyzed with FlowJo software
(TreeStar, Ashland, OR).
RNA isolation and qPCR. RNA was isolated using the Qiagen
Plus Micro Kit (Qiagen, Venlo, the Netherlands) and converted to
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cDNA via reverse transcriptase by random hexamers and MuLV
transcriptase (Applied Biosystems, Foster City, CA). Samples
were subjected to real-time PCR analysis on PRISM 7000
Sequencer Detection System (Applied Biosystems) under
standard conditions. The primers used for the human AHI1
were purchased from Applied Biosystems: isoform A forward
Figure 1 SNAP plot of the chromatin state overlapping the SNPs in LD with the AHI1 cis-eQTL and MS
susceptibility variant, rs4896153 in CD41 T cells
(A) Naive (CD41CD252CDRA1) andmemory (CD41CD252CDRA2) CD41 T cell–specific chromatin statemapping was generated
using the chromHMM algorithm in 1-Mb and 100-kb views surrounding the AHI1 locus. ChIP-seq data generated by the
ENCODE/ROADMAP project reveal various chromatin marks including enhancers, heterochromatin, and polycomb, and various
transcription marks are color coded. All the discovered SNPs from dbGAP137 are listed including their p value of association to
MS, the recombination rate. The LD structure is represented in the r-square value calculated from the Broad SNAP server and is
assigned in red. The strongest MS-associated variant rs4896153 (green) and the strongest eQTL variant rs6908428 are
labeled. (B) Zoom in of the region overlapping the rs13197384 showing the chromatin state in naive andmemory T cells. eQTL5
expression quantitative trait locus; LD 5 linkage disequilibrium; TSS 5 transcription start site.
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primer 59- CCAGCTAATCATGTGGCTAGTGAAACACTG-39;
reverse primer 59 CCTCAGGGCTTAAAGGAGGGGATGC-39;
isoform B forward primer 59- TCAGACCGACAGTCACTTT
GCTGAA-39; and reverse primer 59 TGGTGGGATCCCA
GGTCGGCTCAGT-39. Values are represented as the difference
in Ct values normalized to b2-microglobulin for each sample as
per the following formula: relative RNA expression 5 (22dCt) 3
103. Murine Ahi1 was measured using commercially available
assays (Applied Biosystems). Relative mRNA abundance was
normalized against Gapdh.
Proliferation assay. Cells were cultured for 48 hours before the
addition of 1 mCi of [3H]-thymidine for 16 hours. The cells were
harvested and quantified using an automated sample harvester
(Perkin-Elmer, Waltham, MA). [3H]-thymidine uptake is ex-
pressed in radiation counts per minute.
Statistical analysis. Statistical analysis was performed using
Prism version 7.0 and R version 3.2.1. Cytokine and gene expres-
sion data were analyzed using unpaired t tests. Results from figure
1A are from Raj et al.11 and represent meta-analysis of cis-eQTLs
at false discovery rate 0.05 in CD41 T cells from 407 individuals.
RESULTS AHI1 locus is associated with MS suscep-
tibility and has a cis-eQTL effect. The AHI1 locus has
long been associated with MS. In 2011, a GWAS
identified rs11154801A with an odds ratio (OR) of
1.13 (p 5 1 3 10213) in the AHI1 locus, and the
association was initially attributed to the MYB gene
based on its proximity to the most associated
variant.13 In a subsequent study using the Immuno-
Chip array, the association with rs11154801A was
replicated (OR 1.11; p 5 2.3 3 1029) and assigned
to the AHI1 gene.2 Neither of these studies densely
genotyped this region; thus, we leveraged results of
a large-scale imputation based meta-analysis of the
IMSGC to identify the most strongly associated sin-
gle nucleotide polymorphisms (SNPs) within this
locus. In this analysis,2 the original lead SNP,
rs11154801A was genome-wide significant (p5 1.03
10212). However, another SNP in the region had
a more statistically significant p value: rs4896153T
(OR 1.15, p 5 1.65 3 10213). These 2 SNPs are in
moderate linkage disequilibrium (LD), with an r2 of
0.55 and D9 of 0.96 in the European panel data of the
1000 Genome Project. Of note, rs4896153 was not
present in either of the previously published studies
that reported rs11154801A as the most associated
SNP.We therefore used rs4896153 as the tag SNP for
this MS susceptibility locus.
Next, we tested whether rs4896153 exhibited a cis-
eQTL effect in any of the nearby genes using a large-
scale data set of naive CD41 T cells from healthy
genotyped individuals. We found that the
rs4896153T risk allele is associated with lower RNA
expression of AHI1 (p 5 2.14 3 10224); however, an
SNP nearby, rs6908428, had a stronger effect (p 5
8.77 3 10231) after correction for batch, age, and/or
gender effects (table 1 and figure e-1, http://links.lww.
com/NXI/A5). These 2 SNPs are in moderate LD,
with an r2 of 0.58 and D9 of 0.98. Of interest,
rs6908428 and rs4896153 did not alter the expression
of the neighboring genes in naive T cells, suggesting
that AHI1 is the main target of these 2 SNPs (table 1).
When rs6908428 and rs4896153 are modeled jointly
with the expression of AHI1 as the outcome in CD41
T cells, the p values are 0.026 and 0.537, respectively.
This result indicates that rs6908428 has a marginally
independent association with the expression of AHI1,
but that rs4896153 does not, and that rs6908428 may
be more likely to be the functional variant. However, 1
technical explanation for the superior eQTL effect of
rs6908428 (MAF 0.3173, 1000 Genomes) is that it
has a better imputation INFO score of 0.96 vs 0.55 for
rs4896153 (MAF 0.3007, 1000 Genomes) in our
sample of 211 subjects. For instance, the MAF of
rs6908428 is much closer to the 1000 Genomes
MAF of 0.31, than the MAF of rs4896153 (0.467).
The lower imputation metric of rs4896153 implies
a less accurate dosage measurement, thereby reducing
power and likely artificially diminishing the level of
statistical significance. In addition, the rs6908428
SNP is also a cis-eQTL for AHI1 in PBMCs of MS
subjects (p 5 2 3 10222).14
To visualize the MS susceptibility LD region asso-
ciated with a cis-eQTL effect on AHI1, an SNAP plot
Table 1 rs4896153 and rs6908428 SNPs influence specifically AHI1
expression but not other neighboring genes in naive CD41 T cells
SNP_label Gene_label p Value 2log10 (p value) False discovery rate
rs4896153 AHI1 2.14684E-24 23.6682 1.71747E-23
rs6908428 AHI1 8.77405E-31 30.0568 1.40385E-29
rs4896153 FAM54A 9.28325E-05 4.0323 0.000495107
rs6908428 FAM54A 0.002694635 2.5695 0.010778541
rs4896153 BCLAF1 0.301578238 0.5206 0.765292219
rs6908428 BCLAF1 0.515228645 0.288 0.765292219
rs4896153 MYB 0.396825891 0.4014 0.765292219
rs6908428 MYB 0.957634977 0.0188 0.957634977
rs4896153 MAP7 0.461636352 0.3357 0.765292219
rs6908428 MAP7 0.420436101 0.3763 0.765292219
rs4896153 ALDH8A1 0.214980961 0.6676 0.687939075
rs6908428 ALDH8A1 0.5261384 0.2789 0.765292219
rs4896153 PDE7B 0.751795982 0.1239 0.91966302
rs6908428 PDE7B 0.718455709 0.1436 0.91966302
rs4896153 HBS1L 0.808351037 0.0924 0.91966302
rs6908428 HBS1L 0.862184081 0.0644 0.91966302
Abbreviation: SNP 5 single nucleotide polymorphism.
Expression quantitative trait locus (eQTL) data were analyzed in naive CD41CD62L1 T cells
isolated from the peripheral blood mononuclear cells of healthy European-American sub-
jects carrying the susceptibility or protective alleles of rs4896153 or rs6908428 (n 5
213). Statistical analyses of log10-transformed values were performed by Spearman rank
correlations.
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was generated (figure 1, A and B). Eleven SNPs (red
and purple) are in an LD block with rs4896153
(green) as the lead MS SNP. Ten SNPs are in strong
LD with this lead SNP and are considered to be the
“critical set” of SNPs that are likely to include the
causal variant. To prioritize variants among this set of
ten SNPs, we first looked at reference epigenomic
data from CD41 T cells. The transcription start site
(TSS) of AHI1 is flanked by enhancer marks in both
naive and memory CD41 T cells, consistent with this
gene’s expression in this cell type (figure 1, A and B).
The SNP rs13197384 (purple) is 4 bp downstream of
the 11 TSS of AHI1 and overlaps with a region of
transcription at the 59 or 39, specifically in naive
CD41 T cells (figure 1, A and B). This SNP is there-
fore highlighted as being in an area of differential
transcriptional activity between naive and memory
T cells by existing reference epigenomic data.15 Next,
we investigated the functional potential of these
SNPs using RegulomeDB and HaploReg V4.2:
rs13197384 (TSS), rs7750586 (upstream), and
rs9399148 (upstream); all have evidence of function-
ality based on these SNPs altering known target se-
quences for DNA-binding motifs and being present
within DNase hypersensitivity sites that mark chro-
mosomal segments bound to a DNA-binding protein
in naive CD41 T cells (supplementary material, table
e-1, http://links.lww.com/NXI/A6). These data pri-
oritize these 3 SNPs for follow-up functional assess-
ment. In an attempt to understand the influence of
the SNP position within the enhancer region in
CD41 T cells, we used the R package motifbreakR
version 1.4.016 to identify putative transcription fac-
tor (TF) binding sites that were likely to be disrupted
by the studied polymorphism. TF motifs were ob-
tained from the JASPAR 2014 database (177 motifs
for homo sapiens),17 and the motifbreakR algorithm
was applied with default settings: the weighted sum
method (weighted by relative entropy) was used to
obtain scores, and putative bindings sites were re-
ported if the scaled score (between 0 and 1) was
greater than or equal to 0.8 for the reference or
alternative allele. Binding sites whose unscaled and
unweighted scores for the reference and alternative
allele did not differ by at least 0.4 were considered as
unaffected by the SNP and not reported (supple-
mentary material, table e-2, http://links.lww.com/
NXI/A7). We identified candidate TFs whose bind-
ing could be affected by the presence of 1 of these 3
SNPs. For instance, the transcription repressor
CTCF also known as 11-zinc finger protein or
CCCTC-binding factor that is involved in the
induction of IFNg signaling18 overlaps the
rs13197384 variant (relative matching score 5 0.
8). These findings suggest that the rs13197384 var-
iant, which is in LD with the lead MS SNP, may be
involved in the regulation of AHI1 transcription in
CD41 T cells.
AHI1 eQTL replication in T cell receptor stimulated
T cells. To study the functional consequences of
rs4896153 and its set of linked SNPs, we investigated
the correlation between the rs4896153T risk allele
and the adaptive immune system of healthy subjects.
We used venous blood from healthy subjects, which
allows for the examination of the immune system
without any confounding effects of systemic inflam-
mation or immune-modulating therapies in patients
with autoimmune diseases.19 Healthy genotyped
subjects free of autoimmune and chronic infectious
diseases were selected from the PGP who were
homozygous for either rs4896153T (risk allele) or
rs4896153A (protective allele). Using microbeads,
naive CD41 T cells were isolated from PBMCs by
negative selection. We first replicated the prior
observation that rs4896153 has a cis-eQTL effect in
naive CD41 T cells (figure 2A). Specifically, the
rs4896153T risk allele showed significantly lower
expression of AHI1 than the rs4896153A protective
allele (r 20.837, p 5 4.29 3 1029, n 5 32), as
measured by quantitative PCR. This cis-eQTL effect
was present for both of the 2 major AHI1 isoforms:
isoform A (figure 2B, mRNA 5 NM_017651.4,
NM_001134830.1, NM_001134831.1; protein 5
NP_001128303.1) and isoform B (figure 2C, mRNA5
NM_001134832.1; protein 5 NP_001128304.1).
AHI1 isoform B lacks the SRC Homology 3 (SH3)
domain that is found in isoform A; SH3 is a signaling
domain involved in mediating the interaction of proteins
involved in signaling pathways.20
To investigate the temporal expression of AHI1 in
CD41 cells, we measured AHI1 in genotyped samples
over time in naive CD41 T cells after T cell receptor
(TCR) stimulation with anti-CD3 and anti-CD28
monoclonal antibodies. We found that AHI1 mRNA
expression is rapidly induced within 4 hours of stim-
ulation then decreases over 24 hours, increasing again
by 48 hours with the cis-eQTL effect remaining sig-
nificant during TCR stimulation (p , 0.01 for all
time points) (figure 2D).
AHI1 risk variant promotes a CD41IFNg1 T cell
phenotype. Previous reports described AHI1 as an
oncogene that enhances cancer cell proliferation.21–26
To investigate the effects of the rs4896153 genotype
on CD41 T cell function beyond RNA expression, we
measured (1) T cell proliferation by [3H]-thymidine
incorporation assays and (2) T cell cytokine profile.
Naive CD41 T cells isolated from PBMCs of healthy
genotyped subjects homozygous for either the AHI1
risk (n 5 8) or protective (n 5 13) alleles were
exposed to TCR stimulation followed by analysis of
T cell proliferation (day 3) and cytokine expression
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(day 7). No significant difference was seen in prolif-
erative capacity between the genotype categories (fig-
ure 3A). Of interest, T cells bearing the rs4896153TT
genotype yielded significantly greater frequency of
IFNg1 T cells than the rs4896153AA genotype in
TCR stimulated cells (p5 0.008) (figure 3B). Within
the IFNg-positive cells, more IFNg was expressed in
cells from subjects with the risk genotype as measured
by mean fluorescence intensity (MFI) (figure 3C),
providing a link between an MS genetic susceptibility
and a proinflammatory T cell phenotype. The effect of
the AHI1 risk allele on T cell phenotype may be spe-
cific to IFNg because we did not find any significant
alteration of IL-17 expression when naive CD41 T
cells carrying the AHI1 risk or protective alleles
were polarized under Th17 cell condition (data not
shown).
Increased IFNg expression in Ahi1 knockout CD41
T cells. To further explore the role of AHI1 in the
regulation of IFNg production by CD41 T cells, we
first measured Ahi1 expression in murine CD41
T cells. Naive CD41 T cells were isolated from
spleens of wild-type (WT) mice, and cells were
TCR stimulated for several time points. RNA lysates
were prepared at each time point, and murine Ahi1
Figure 3 Decreased AHI1 in human CD41 T cells is associated with decreased proliferation and increased
IFNg production
(A) Naive CD41 T cells were isolated from the peripheral blood of healthy subjects bearing risk (TT), protective (AA), or
heterozygous (AT) alleles for rs4896153, and cells were activated with anti-CD3/CD28 followed by the analysis of cell
proliferation by [3H]-thymidine incorporation 60 hours after stimulation. (B, C) A subset of these cells was further stimulated
for 7 days, and IFNg cytokine expression was measured by flow cytometry. (B) Frequency of CD41IFNg1 T cells bearing risk
(TT) or protective (AA) alleles for the rs4896153 was analyzed by intracellular staining using flow cytometry. (C) Mean
fluorescent intensity (MFI) of IFNg expression from the activated T cells is shown. p Values were generated using Student’s
t test. Each dot represents an individual. Data are represented as mean 6 SEM. IFNg 5 interferon gamma.
Figure 2 The MS risk allele rs4896153T is associated with decreased AHI1 expression in naive CD41 T cells and T cell receptor–stimulated
CD41 T cells
(A) Naive CD41 T cells were isolated from the peripheral blood of healthy subjects bearing risk (TT), protective (AA), or heterozygous (AT) genotypes for
rs4896153, andAHI1 expression wasmeasured by Taqman qPCR. The 2major isoforms ofAHI1 (B) isoformA (mRNA5NM_017651.4, NM_001134830.1,
NM_001134831.1; protein5NP_001128303.1) and (C) isoform B (mRNA5 NM_001134832.1; protein5NP_001128304.1) were measured in genotype
individuals from (1A) by SYBR green qPCR. (D) Naive CD41 T cells were stimulated with anti-CD3/CD28 for 0–48 hours, and AHI1 expression was measured
by Taqman qPCR. Comparing the AA and TT genotypes, all data points are p , 0.01. Each dot represents an individual. Data are represented as mean 6
SEM.
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mRNA expression was assessed by quantitative PCR.
In agreement with AHI1 expression in activated
human CD41 T cells, we found that the mRNA
levels of murine Ahi1 are moderately induced on
TCR activation (4–6 hours) but rapidly decreased
later as shown at 24–72 hours, suggesting a regulatory
role of Ahi1 in the differentiation, phenotype, or
function of CD41 T cells (figure 4A and figure e-2A,
http://links.lww.com/NXI/A5). Similarly, the rapid
but reversible increase in Ahi1 expression was also
observed in CD41T cells polarized under Th1 cells,
a T cell subset that is known to express IFNg1 T
cells.
Next, we took advantage of total Ahi1 knockout
(Ahi12/2) mice27 to measure the role of Ahi1 in T cells
using Ahi1 genetic deletion. Spleens were dissected from
Ahi12/2 and WT littermates, and naive CD41 T cells
were sorted and activated with mouse specific anti-
CD3/CD28 antibodies. We found that, using a more
physiologic stimulation that does not bypass costimula-
tory pathways (low anti-CD3/CD28 concentrations,
each mAb at 0.25 mg/mL), CD41 T cells from
Ahi12/2 mice exhibited impaired cell proliferation com-
pared with their WT counterparts (figure 4B). Strik-
ingly, we detected increased frequency of IFNg-
producing T cells in Ahi12/2 T cells (figure 4C), an
effect that is in agreement with the human data. To
study whether Ahi1 regulates T cell cytokine production
under polarizing conditions, we analyzed IFNg and IL-
17A expressions in CD41 T cells polarized toward
a proinflammatory Th1 or Th17 fate. There was a trend
implicating a modest increase in IFNg1 frequency
among Th1 cells (figure e-3A, http://links.lww.com/
NXI/A5). Moreover, analysis of IL-17A in Ahi12/2
T cells polarized under Th17 condition did not reveal
any significant alteration of IL-17A expression in the
absence of Ahi1 (figure e-3B, http://links.lww.com/
NXI/A5). Altogether, these findings suggest that Ahi1
regulates specifically IFNg-producing CD41 T cells in
the absence of exogenous polarizing molecules.
DISCUSSION Rare mutations in AHI1/Ahi1 have
been reported to cause Joubert syndrome, a ciliopathic
disorder, characterized by malformations of the cere-
bellar vermis and brainstem as well as clinical mani-
festations that include, breathing irregularities,
hypotonia, developmental delays, and ocular motor
apraxia.28 The AHI1 protein contains an N-terminal
coiled-coil domain, 7 WD40 domains, and an SH3
domain; it is the only protein known to contain both
a WD40 domain and an SH3 domain, suggesting
a novel role in cell signaling for this protein.29 In
chronic myeloid leukemia cells, AHI1 knockdown
showed reduced TNFa, IL-4, and IL-2 cytokine
production.30 On the other hand, overexpression of
AHI1 conferred a growth advantage,25 which is con-
sistent with our mouse data in which reduced Ahi1
expression in CD41 T cells was associated with
reduced proliferative capacity. However, the decrease
in AHI1 expression did lead to increased cytokine
production at least for IFNg, suggesting that the role
of AHI1 in primary human T cells may involve dis-
tinct signaling pathways in comparison with tumor
cells. In MS, proinflammatory cytokines such as
IFNg, IL-17, IL-22, and GM-CSF are present in
elevated amounts in the CSF and CNS lesions of MS
patients compared with healthy controls, especially
during the active phase of the disease.31–34 The
Figure 4 Ahi1 genetic deficiency decreases T cell proliferation and upregulates IFNg production
(A) Ahi1mRNA expression in activated T cells. Wild-type (WT) naive CD41 T cells were isolated from the spleens of naive WT
mice, and cells were activated with anti-CD3/CD28 for up to 72 hours (h). Ahi1mRNA expression wasmeasured by Taqman
and calculated relatively to the house keeping geneGapdh. (B, C) Effects of Ahi1 on T cell proliferation and IFNg expression.
Naive CD41 T cells were isolated from the spleens of Ahi12/2 or WT littermates, and cells were activated with anti-CD3/
CD28 (0.25 mg/mL) for (B) 60 hours to measure T cell proliferation by [3H]-thymidine incorporation or for (C) 4 days to
measure IFNg production by intracellular staining using flow cytometry. Data represent the average of 3 independent
experiments. Each dot represents a mouse. Data are represented as mean 6 SEM. IFNg 5 interferon gamma.
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frequency of IFNg vs IL-17 responses in EAE can
influence the localization of inflammation in the
CNS.35 Robust Th1 responses producing elevated
levels of IFNg induced CD41 T cell infiltration in
the spinal cord. By contrast, high IL-17 levels caused
CD41 T cell infiltration preferentially into the brain
parenchyma and induced atypical EAE.5 In our study,
although the AHI1 risk variant was associated with an
increase in IFNg production by CD41 T cells, we did
not detect a significant alteration in IL-17 levels. It
should be noted that recent studies in several
immunologic diseases including sarcoidosis and
Crohn disease identified a subset of pathogenic
IFNg-producing Th17 cells called Th17.1 cells ex-
pressing chemokine receptors CCR6 and
CXCR3.36,37 These cells are believed to be derived
from classically polarized Th17 cells and differentiate
into a Th1-like phenotype in which they produce
significant IFNg but little amounts of IL-17.38 Of
interest, in patients with MS, circulating Th17 cells
that respond to myelin peptides express high levels of
IFNg, suggesting that these autoreactive T cells are
plastic and express distinct cytokine profiles from that
identified in vitro.39 A more extensive cytokine
characterization of CD41 T cells expressing the AHI1
risk variant may address this issue further.
In this study, we confirm that rs4896153, an MS
susceptibility variant, has a strong cis-eQTL effect on
overall AHI1 mRNA expression, affecting both AHI1
isoforms, and that this effect is maintained for at least
48 hours after TCR stimulation. To assess the func-
tional outcome of this SNP on CD41 T cells, we
measured proliferation and cytokine production fol-
lowing TCR stimulation. While we did not see a sig-
nificant allelic difference in proliferation of human
T cells, we consistently saw visibly less cell clonal
expansion in the rs4896153TT cultures, an effect
noticeable after only 24 hours of differentiation (data
not shown). We postulate a role for AHI1 early on in
TCR activation, given its peak mRNA expression 4–6
hours after anti-CD3/CD28 stimulation of both
mouse and human CD41 T cells. AHI1 is localized
to the mother centriole, and for TCR signaling, the
reorientation and movement of the centriole and asso-
ciated Golgi apparatus toward the contact area between
a T cell and an antigen-presenting cell is required after
an initial contact.40 It is therefore possible that AHI1,
being localized to the mother centriole and involved in
actin organization, may play a role in the formation or
stabilization of the TCR synapse, which could be
a mechanism for its association with MS.
Identification of the causal variant (the SNP/s that
affect the trait), and determining their exact mecha-
nism of action, is one of the main challenges and pro-
vides the next step in GWAS interpretation.41 Our
analysis of the GWAS identified MS variants near
the AHI1 gene and prioritized an LD block with sev-
eral SNPs that are associated with decreased AHI1
expression in CD41 T cells carrying the MS risk allele.
We identified 3 SNPs, rs13197384, rs7750586, and
rs9399148, with suggestive functionality based on (1)
being present within DNase hypersensitivity sites
and (2) the potential alteration of TF binding to their
DNAmotifs in CD41 T cells. We identified candidate
TFs whose binding could be affected by the presence
of 1 of these 3 SNPs including the transcription
repressor CTCF that is involved in the induction of
IFNg signaling18 in which the CTCF consensus bind-
ing site overlaps with rs13197384. Further functional
studies, such as minigene reporter assays, are warranted
to identify causal variants that influence a disease trait
in MS.
We report that the rs4896153T allele reduces
AHI1 RNA expression and is associated with a greater
percentage of IFNg-producing CD41 T cells. While
additional functional studies are required to further
delineate the role of AHI1 in MS susceptibility, our
results expand the repertoire of dysfunctional cyto-
kine responses that are genetically implicated in MS
susceptibility and may help establish a scaffold on
which to assemble other susceptibility variants.
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